Advances in Cancer Drug Targets. (Record no. 109364)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 07938nam a22004813i 4500 |
| 001 - CONTROL NUMBER | |
| control field | EBC4504170 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | MiAaPQ |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20240729130433.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d | |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr cnu|||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 240724s2016 xx o ||||0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9781681082332 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 9781681082349 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (MiAaPQ)EBC4504170 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (Au-PeEL)EBL4504170 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (CaPaEBR)ebr11204301 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)948924406 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | MiAaPQ |
| Language of cataloging | eng |
| Description conventions | rda |
| -- | pn |
| Transcribing agency | MiAaPQ |
| Modifying agency | MiAaPQ |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RC271.C5 -- .A383 2016eb |
| 082 0# - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 616.99406099999999 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Atta-ur-Rahman. |
| 245 10 - TITLE STATEMENT | |
| Title | Advances in Cancer Drug Targets. |
| 250 ## - EDITION STATEMENT | |
| Edition statement | 1st ed. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | Sharjah : |
| Name of producer, publisher, distributor, manufacturer | Bentham Science Publishers, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2016. |
| 264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | ©2016. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (278 pages) |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 490 1# - SERIES STATEMENT | |
| Series statement | Advances in Cancer Drug Targets ; |
| Volume/sequential designation | v.3 |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Intro -- CONTENTS -- PREFACE -- List of Contributors -- Neutrophil Elastase as a Target in Lung Cancer: the State of the Art -- 1. INTRODUCTION: NEUTROPHIL ELASTASE/Α-1ANTITRYPSIN IMBALANCE AS A LINK BETWEEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND LUNG CANCER -- 2. MULTIFACETED FUNCTIONS OF NEUTROPHIL ELASTASE IN LUNG CANCER -- 3. ENDEGNENOUS NEUTROPHIL ELASTASE INHIBITORS -- 3.1. Proteinaceous Inhibitors -- 3.2. Natural Compounds -- 3.2.1. Glycosaminoglycans -- 3.2.2. Phenolics -- 3.2.3. Triterpenoids -- 3.2.4. Fatty Acids and Peptide Derivatives -- 4. DESIGN OF DUAL NEUTROPHIL ELASTASE / MMP INHIBITORS -- DESIGN OF DUAL HNE-MMP INHIBITORS -- CONCLUDING REMARKS -- ADDITIONAL MATERIAL -- 1. Molecular Modeling and Molecular Graphics -- 2. Ligand and Receptor Preparation -- 3. Docking Protocol -- CONFLICT OF INTEREST -- DISCLOSURE -- ACKNOWLEDGEMENTS -- ABBREVIATIONS -- REFERENCES -- Inhibition of Membrane Complement Inhibitor Expression (CD46, CD55, CD59) by siRNA Sensitizes Tumor Cells to Complement Attack -- INTRODUCTION -- MATERIALS AND METHODS -- Cell Culture -- SiRNA Sequences -- SiRNA Transfection -- Flow Cytometry -- Complement-mediated Cytotoxicity Assay (CDC) -- C3-binding Studies -- Real-Time RT-PCR -- Statistical Analysis -- RESULTS -- Design of siRNAs Specific for CD46, CD55 and CD59 -- SiRNA-mediated Downregulation of mCRP Expression -- siRNA-mediated Augmentation of Tumor Cell Complement Lysis and Opsonization -- Time-course of siRNA-induced mCRP Inhibition -- Stable Downregulation of CD59 Using an Hairpin siRNA Expression Vector -- DISCUSSION -- CONFLICT OF INTEREST -- DISCLOSURE -- ACKNOWLEDGEMENT -- ABBREVIATIONS -- REFERENCES -- Points of Therapeutic Intervention along the Wnt Signaling Pathway in Hepatocellular Carcinoma -- INTRODUCTION -- THE WNT SIGNALING PATHWAY -- Overview of the Wnt Signaling -- The Wnt/β-catenin Pathway. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Aberrant Activation of the Wnt/β-catenin Pathway in HCC -- TARGETING THE WNT/Β-CATENIN PATHWAY IN HCC -- Targeting the Upstream Components -- Endogenous Inhibitors of the Ligand/Receptor Complex -- Targeting Wnt Ligands and FZD Receptors -- Targeting the Dishevelled Protein -- Cellular Trafficking and Targets -- Targeting the β-catenin Destruction Complex -- Targeting the β-catenin/TCF Transcriptional Complex -- Pitfalls in Targeting the Wnt/β-catenin Pathway -- CONCLUSIONS AND PERSPECTIVES -- CONFLICT OF INTEREST -- DISCLOSURE -- ACKNOWLEDGMENT -- ABBREVIATIONS -- REFERENCES -- Collaboration of Epithelial Mesenchymal Transition and Cancer Stem Cells: Sinister Routes for Chemoresistant Recurrent Ovarian Cancer -- INTRODUCTION -- PATHOLOGY OF OVARIAN CANCER -- TRANSITION FROM EPITHELIAL TO MESENCHYMAL PHENOTYPE AND THE PROGRESSION OF CANCER -- EVIDENCE OF EMT IN OVARIAN CANCER -- STEM CELLS IN NORMAL OVARIES AND OVARIAN CANCER -- SPHERE FORMATION AND THE CANCER STEM CELL PHENOTYPE OF THE OVARY -- ASSOCIATION OF EMT AND CSCS: A MERGER FOR POTENTIAL CHEMORESISTANCE IN OVARIAN CANCER -- Cisplatin Induced EMT Generates Ovarian Cancer Stem-Like Cells: A Study on the OVCA 433 Cell Line as an Experimental Model -- NEW THERAPEUTIC APPROACHES AND CONCLUSION -- CONFLICT OF INTEREST -- DISCLOSURE -- ACKNOWLEDGEMENTS -- ABBREVIATIONS -- REFERENCES -- Oxaliplatin-mediated Inhibition of Survivin Increases Sensitivity of Head and Neck Squamous Cell Carcinoma Cell Lines to Paclitaxel -- INTRODUCTION -- MATERIALS AND METHODS -- Cell Culture -- Plasmid and Antisense Transfection Efficiency -- Drug Treatment -- MTT (methylthiazolyldiphenyl-tetrazolium bromide) Assay -- Western Blot Analysis -- Real-Time PCR -- TUNEL (Terminal Deoxyribonucleotidyl Transferase Mediated dUTP Nick End Labeling) Assay -- Statistical Analysis -- RESULTS. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Detection of Survivin Gene Expression -- Effect of Paclitaxel and Oxaliplatin on Cell Growth and Survival -- Survivin Expression Reduces Paclitaxel-mediated Cytotoxicity -- Oxaliplatin Sensitizes Cancer Cells to Paclitaxel by Inhibiting Survivin -- Inhibition of Survivin by a siRNA Method Induces Paclitaxel-mediated Cell Death -- DISCUSSION -- CONFLICT OF INTEREST -- DISCLOSURE -- ACKNOWLEDGEMENTS -- ABBREVIATIONS -- REFERENCES -- Melatonin Inhibits the Growth of DMBA-induced Mammary Tumors by Regulating Estrogen Sulfatase Enzyme -- INTRODUCTION -- MATERIAL AND METHODS -- Animals and Housing Conditions -- Tumor Induction -- Experimental Design -- Surgical Treatments, Tumor Size and Number, Survival Rates and Autopsy Procedures -- Estrone Sulfate and Melatonin Treatments -- Measurement of Steroid Sulfatase Activity -- Measurement of mRNA Expression of Sulfatase -- Statistical Analysis -- RESULTS -- Histopathology of Mammary Tumors -- Evolution of Body Weight -- Tumor Growth -- Survival Probability -- Serum Estradiol Concentration and Uterine Weight -- Sulfatase Activity and Expression -- DISCUSSION -- CONFLICT OF INTEREST -- DISCLOSURE -- ACKNOWLEDGEMENTS -- REFERENCES -- Role of mTOR Signaling in Tumor Cell Motility, Invasion and Metastasis -- INTRODUCTION -- mTOR Strcture and Signaling Complexes -- mTOR Signaling Complexes -- mTORC1 -- mTORC2 -- mTOR Inhibitors -- The Role of mTOR Signaling Pathway in Cell Motility and Invasion -- mTORC1 Signaling in Cell Motility and Invasion -- mTORC2 Signaling in Cell Motility and Invasion -- Rapamycin and Tumor Metastases -- SUMMARY -- CONFLICT OF INTEREST -- DISCLOSURE -- ACKNOWLEDGMENTS -- REFERENCES -- Structure-Activity Studies on Arylamides and Arysulfonamides Ras Inhibitors -- INTRODUCTION -- RESULTS AND DISCUSSION -- Chemistry -- Biochemistry. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Interaction between Compound 1 (SCH-53870) and Ras: Preliminary Observations -- Nucleotide Exchange Inhibition Experiments with Compounds 1-17 -- Effect of Compounds 1-4 on Mammalian Cell Growth -- COMPUTATIONAL ANALYSIS -- Docking Calculations -- CONCLUSION -- MATERIALS AND METHODS -- Expression and Isolation of Proteins -- Measurement of GEF-Stimulated Guanine Nucleotide Exchange on p21 h-Ras -- Measurement of Dissociation Rate -- Two-Hybrid System -- Cell Cultures and Growth Conditions -- Docking Calculations -- SUPPLEMENTARY MATERIAL -- CONFLICT OF INTEREST -- DISCLOSURE -- ACKNOWLEDGMENTS -- ABBREVIATIONS -- REFERENCES -- SUBJECT INDEX. |
| 588 ## - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Description based on publisher supplied metadata and other sources. |
| 590 ## - LOCAL NOTE (RLIN) | |
| Local note | Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Cancer--Chemotherapy. |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version: |
| Main entry heading | Atta-ur-Rahman |
| Title | Advances in Cancer Drug Targets |
| Place, publisher, and date of publication | Sharjah : Bentham Science Publishers,c2016 |
| International Standard Book Number | 9781681082349 |
| 797 2# - LOCAL ADDED ENTRY--CORPORATE NAME (RLIN) | |
| Corporate name or jurisdiction name as entry element | ProQuest (Firm) |
| 830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE | |
| Uniform title | Advances in Cancer Drug Targets |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=4504170">https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=4504170</a> |
| Public note | Click to View |
No items available.